10-K: Zimmer Biomet Reports 2024 Results, Announces Acquisition of Paragon 28

Zimmer Biomet's 2024 results show a net sales increase of 3.8% and the company plans to acquire Paragon 28, Inc.

Summary

• Zimmer Biomet's net sales increased by 3.8% in 2024 compared to 2023, driven by market growth, new product introductions, positive price realization, and commercial execution.
• The company experienced operational challenges due to the transition to a new enterprise resource planning (ERP) software system, which had less than a one percent impact on net sales for the full year 2024.
• Net earnings were $903.8 million in 2024, a decrease from $1,024.0 million in 2023, due to higher tax settlements in 2023, charges from the 2023 Restructuring Plan, and higher intangible asset amortization.
• The company expects year-over-year revenue growth of 1.0% to 3.5% in 2025, driven by market growth, new product introductions, and commercial execution.
• Foreign currency is expected to negatively affect year-over-year net sales by approximately 1.5% to 2.0% in 2025.
• Operating profit is estimated to increase in 2025 due to higher net sales, leverage from fixed operating expenses, ongoing savings from restructuring plans, and lower employee termination charges.
• In January 2025, Zimmer Biomet entered into a definitive agreement to acquire Paragon 28, Inc. for approximately $1.2 billion, expected to close in the first half of 2025.
• The company issued senior notes in February 2025 to fund the Paragon 28 acquisition and for general corporate purposes.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is revenue growth and a planned acquisition, there are also challenges with earnings, restructuring costs, and ERP implementation. The outlook is cautiously optimistic.

Positives

• Net sales increased by 3.8% in 2024, driven by market growth and new product introductions.
• The company expects revenue growth of 1.0% to 3.5% in 2025.
• Operating profit is estimated to increase in 2025.
• The acquisition of Paragon 28, Inc. is expected to expand the company's presence in the foot and ankle market.
• The company is realizing savings from restructuring plans and cost reduction initiatives.
• The company is returning cash to investors through share repurchases and dividends.

Negatives

• Net earnings decreased in 2024 due to higher tax settlements in 2023, restructuring charges, and higher intangible asset amortization.
• The transition to a new ERP system caused operational challenges and negatively impacted net sales.
• Foreign currency exchange rates had a negative effect of 1.0% on year-over-year sales in 2024.
• The company incurred $219.0 million in restructuring expenses in 2024.
• The company experienced higher bad debt-related charges due to a bankruptcy at a significant U.S. healthcare system.

Risks

• The company operates in a highly competitive environment.
• The company is subject to extensive government regulation.
• The company faces risks related to product liability claims and intellectual property litigation.
• The company's international operations are subject to various risks, including currency fluctuations and political instability.
• The company is dependent on sophisticated information technology and faces cybersecurity risks.
• The company has a substantial amount of debt.
• Changes in tax laws could negatively impact the company's effective tax rate.
• The company is involved in various litigation matters that may result in adverse outcomes.

Future Outlook

Zimmer Biomet expects year-over-year revenue growth of 1.0% to 3.5% in 2025. Operating profit is estimated to increase in 2025. The acquisition of Paragon 28 is expected to close in the first half of 2025.

Management Comments

• Net sales growth was driven by a combination of market growth, new product introductions, positive price realization and commercial execution across the organization.
• Shipping levels returned to similar levels that existed prior to the implementation by the end of the year.

Industry Context

The orthopedics and broader musculoskeletal care industry is highly competitive, with major competitors including Johnson & Johnson MedTech, Stryker Corporation, and Smith & Nephew plc. Competition is primarily based on technology, innovation, quality, reputation, customer service, and pricing.

Comparison to Industry Standards

• Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc are major competitors in the global markets for knees, hips, and S.E.T. products.
• The company's performance is influenced by healthcare cost containment measures, similar to other companies in the medical device industry.
• The company's global operations are subject to risks from international trade and tariff policies, similar to other multinational corporations.

Legal Proceedings

• The company is involved in various legal proceedings, including product liability, intellectual property, stockholder matters, tax disputes, commercial disputes, employment matters, whistleblower and qui tam claims and investigations, governmental proceedings and investigations, and other legal matters that arise in the normal course of business.

Stakeholder Impact

• The company's performance impacts shareholders through stock value, dividends, and share repurchases.
• The company's restructuring plans and acquisitions may impact employees.
• The company's products and solutions impact patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues.
• The company's relationships with healthcare professionals are subject to scrutiny and regulation.

Next Steps

• Complete the acquisition of Paragon 28, Inc. in the first half of 2025.
• Continue executing on the 2023 Restructuring Plan.
• Address the proposed adjustments from the IRS for tax years 2013-2015 and 2016-2019.
• Monitor and enhance cybersecurity program, processes, techniques and procedures to combat evolving and adaptive cybersecurity threats.

Key Dates